सभी अध्ययन
सक्रिय लेकिन भर्ती नहींचरण2, चरण3हस्तक्षेपात्मक

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative colitis is a long-term condition that causes inflammation, pain, and bleeding in the large bowel. While there are treatments available, they do not work for everyone, and symptoms can still disrupt daily life. This clinical study is testing a medicine called guselkumab for adults with moderately to severely active ulcerative colitis. Guselkumab works by targeting a specific protein in the body's immune system to help reduce gut inflammation and allow the bowel lining to heal. Researchers are comparing guselkumab against a placebo (an inactive dummy treatment) to test how well it works and check for side effects. The study is aimed at people whose previous colitis treatments did not work well or caused uncomfortable side effects. Taking part involves regular health check-ups and close monitoring by a specialist medical team.

एक नजर में

स्थिति
सक्रिय लेकिन भर्ती नहीं
चरण
चरण2, चरण3
प्रायोजक
जैनसेन अनुसंधान और विकास, एलएलसी
नामांकन लक्ष्य
1,064
प्रारंभ
26 Sep 2019
अनुमानित पूर्णता
16 Jul 2027

परिणाम

इस अध्ययन के परिणाम

प्रकाशित November 2024

इस अध्ययन के परिणाम प्रकाशित कर दिए गए हैं।.

प्राथमिक परिणाम
Induction Study 1: Percentage of Participants With Clinical Response at Week I-12
Clinical response was defined as a decrease from induction baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1 point decrease from baseline (Week 0 of IS-1) in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for specified arms only.
रजिस्ट्रि पर पूर्ण परिणाम

यह अध्ययन किस बारे में है?

Ulcerative colitis is an ongoing condition where the lining of the large bowel becomes red, swollen, and ulcerated. People living with it often face sudden urges to use the toilet, diarrhoea containing blood, tummy cramps, and deep tiredness. Although many medicines can help manage flare-ups, some people find that their current treatments either stop working over time or cause unwanted side effects. Finding new ways to calm the gut is essential for long-term health.

This trial is looking at an experimental medicine called guselkumab. In people with ulcerative colitis, the immune system mistakenly attacks the lining of the bowel, driven by certain chemical signals. Guselkumab is designed to block one of these key signals, helping to dampen down inflammation so the gut can heal. In this study, some participants will receive guselkumab while others receive a placebo, which looks identical but contains no active drug.

This is a late-stage study, meaning researchers need to gather reliable evidence on how well the medicine works across a larger group of people and check its overall safety. Taking part helps scientists understand whether guselkumab could become a useful new prescription option in the UK for people struggling to keep their colitis under control.

मुख्य निष्कर्ष

  • The study tests whether guselkumab can reduce gut inflammation in moderate to severe ulcerative colitis.
  • It is aimed at adults whose previous colitis treatments did not work well or were hard to tolerate.
  • Participants will be randomly chosen to receive either guselkumab or a dummy treatment (placebo).
  • You will receive close medical monitoring and expert care throughout the study.
  • Joining is entirely your choice, and you are free to leave the trial at any time.

कौन पात्र हो सकता है?

This study is open to adults aged 18 and older who have a clear diagnosis of moderate to severe ulcerative colitis. To qualify, you must have tried standard medical therapies that either did not control your symptoms well enough or caused side effects that meant you had to stop taking them. You will also need to have routine health tests, such as blood checks, to ensure taking part is safe for you.

You cannot join this study if your inflammation is only in the rectum or affects less than 20 centimetres of your bowel. It is also not suitable for people with other types of bowel inflammation, such as Crohn's disease, or anyone who currently has a stoma bag or an abnormal tunnel in the bowel wall known as a fistula. Certain medications are also not allowed during the trial.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. मेरी उम्र 18 वर्ष या उससे अधिक है।.
  2. I have a confirmed diagnosis of ulcerative colitis with active symptoms.
  3. My previous bowel treatments have not worked well or caused intolerable side effects.
  4. My inflammation spreads further than just my rectum (more than 20 cm into the bowel).
  5. I do not have Crohn's disease, a stoma bag, or a fistula.
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you take part, you will first have a screening period to check your overall health and confirm that the study is safe for you. This will include blood tests, stool samples, and an examination of your bowel lining. During the trial, you will be randomly assigned to receive either guselkumab or a dummy treatment (placebo). You will need to attend hospital clinic visits for health checks, symptom reviews, and study medication doses, which may be given through a drip into a vein or as an injection under the skin. You will also be asked to keep a simple diary tracking your bowel habits. The trial typically lasts for several months up to a year, followed by a safety check-up once treatment ends.

संभावित जोखिम और लाभ

The possible benefit of joining is that the study medicine may help calm your bowel inflammation and ease your symptoms, though this cannot be guaranteed. You will also receive frequent, detailed health monitoring from bowel specialists. The main risks include side effects from the study drug, such as mild injection site reactions, headaches, or a slightly higher risk of common infections like colds. Because this is a controlled trial, you might also receive the placebo rather than the active medicine. You are free to leave the study at any time without giving a reason, and your normal NHS care will not be affected.

Locations (392)

  • Om Research LLC
    सत्यापित पोस्टकोड
    Lancaster, United States
  • UCLA
    सत्यापित पोस्टकोड
    लॉस एंजेलेस, संयुक्त राज्य अमेरिका
  • Peak Gastroenterology Associates 1
    सत्यापित पोस्टकोड
    Colorado Springs, United States
  • Florida Research Network, LLC
    सत्यापित पोस्टकोड
    गेन्सविल, संयुक्त राज्य अमेरिका
  • University of Florida Health Jacksonville
    सत्यापित पोस्टकोड
    गेन्सविल, संयुक्त राज्य अमेरिका
  • Harmony Medical Research Institute, Inc.
    सत्यापित पोस्टकोड
    हियालिया, संयुक्त राज्य अमेरिका
  • UF Health Jacksonville Gastroenterology Emerson
    सत्यापित पोस्टकोड
    जैक्सनविल, संयुक्त राज्य अमेरिका
  • I.H.S. Health. LLC
    सत्यापित पोस्टकोड
    Kissimmee, United States
  • Columbus Clinical Services LLC
    सत्यापित पोस्टकोड
    मियामी, संयुक्त राज्य अमेरिका
  • Vista Health Research, LLC
    सत्यापित पोस्टकोड
    मियामी, संयुक्त राज्य अमेरिका
  • ऑरलैंडो हेल्थ
    सत्यापित पोस्टकोड
    ऑरलैंडो, संयुक्त राज्य अमेरिका
  • Care Access Research, Orlando
    सत्यापित पोस्टकोड
    ऑरलैंडो, संयुक्त राज्य अमेरिका

सामान्य प्रश्न

What is a placebo and why is it used?

A placebo looks just like the real medicine but contains no active ingredients. Researchers use it to see if changes in health are truly caused by the study drug or by other factors.

Will I have to pay for the study treatment?

No. All study medications, tests, and doctor visits related to the trial are provided free of charge, and travel expenses are often covered.

Do I have to stop taking all my regular medicines?

Not necessarily, but some specific gut medicines cannot be taken alongside the study drug. The trial doctor will review all your current treatments to see what is safe.

What happens if my colitis gets worse during the trial?

Your safety comes first. If your symptoms flare up or get noticeably worse, the study team will step in and can switch you to standard medical care immediately.

अगर मैं अपना मन बदल लूँ तो क्या मैं अध्ययन छोड़ सकता हूँ?

Yes. Taking part is completely voluntary. You can withdraw at any point, and your standard NHS treatment will continue as normal.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.